

業 績 目 録（令和5年）

大学院科目名：血液内科学

(A-a) 英文著書

なし

(A-b) 和文著書

- 1 黒田純也, 水谷信介. 多発性骨髄腫と類縁疾患. *がん 最新の薬物療法 2023-2024*. 石岡千加史 監. 南江堂, 東京 : pp226-228, 2023.

(B-a) 英文総説

なし

(B-b) 和文総説

- 1 黒田純也. CAR-T 細胞療法時代の多発性骨髄腫治療の臨床と研究の新たな課題 Emerging Clinical and Research Issues in the Era of CAR-T Cell Therapy for Multiple Myeloma. *日本造血・免疫細胞療法学会雑誌* 12 : 213-221, 2023.
- 2 黒田純也. 序文. *日本臨牀増刊号. 新リンパ腫学* : 1-3, 2023.
- 3 黒田純也, 岡本明也. 多発性骨髄腫における treatment-free の位置づけ. *血液内科* 86 : 656-661, 2023.
- 4 黒田純也. 骨髄腫進展と治療抵抗性獲得の病態. Pathophysiology and mechanisms underlying the disease progression and the acquisition of the therapeutic resistance in multiple myeloma. *日本臨牀* 81 : 813-818, 2023.
- 5 塚本拓. 多発性骨髄腫に対する CAR-T 細胞療法の開発状況と今後の展望. Update and perspective of CAR-T cell therapy for multiple myeloma. *血液内科* 87 : 439-444, 2023.
- 6 塚本拓. 多発性骨髄腫の R2-ISS. Second revision of the International staging system (R2-ISS) in multiple myeloma. 86 : 883-888, 2023.
- 7 塚本拓. 形質細胞腫瘍の家族歴を有する形質細胞腫瘍患者の予後. Prognostic impact of family history of plasma cell disorders in patients with MGUS, multiple myeloma, and systemic AL amyloidosis.

血液内科 86 : 260-265, 2023.

- 8 塚本拓. 多発性骨髄腫における細胞遺伝学異常の温故知新. New concepts in multiple myeloma by returning to cytogenetics. 臨床血液 64 : 411-417, 2023.
- 9 塚本拓. マントル細胞リンパ腫の病態形成と分子腫瘍学的異常. 日本臨牀増刊号. 新リンパ腫学 : 64-70, 2023.
- 10 藤野 貴大. 腸管 T 細胞リンパ腫. 日本臨牀増刊号. 新リンパ腫学 : 352-356, 2023.
- 11 水谷 信介. 皮下脂肪織炎様 T 細胞リンパ腫. 日本臨牀増刊号. 新リンパ腫学 : 362-365, 2023.

(C-a) 英文原著

- 1 Takeuchi H, Inaba T, Shishido-Hara Y, Tsukamoto T, Mizutani S, Okamoto T, Tanigawa S, Yamanaka T, Takahashi Y, Konishi E, Kuroda J, Hashimoto N. Analysis of False-negative Findings of the Incomparable Accuracy and Swiftness of Flow Cytometric Diagnosis of Primary Central Nervous System Lymphoma. *Neurol Med Chir (Tokyo)*, 63: 495-502, 2023. (IF= 2.4)
- 2 Nakaya A, Shibayama H, Uoshima N, Yamamura R, Yoshioka S, Imada K, Shimura Y, Hotta M, Matsui T, Kosugi S, Hanamoto H, Uchiyama H, Yoshihara S, Fuchida S, Onda Y, Tanaka Y, Ohta K, Matsuda M, Kanda J, Yoko A, Kiyota M, Kawata E, Takahashi R, Fukushima K, Tanaka H, Yagi H, Takakuwa T, Hosen N, Ito T, Shimazaki C, Takaori-Kondo A, Kuroda J, Matsumura I, Hino M. Impact of cytogenetic abnormalities in symptomatic multiple myeloma; a Japanese real-world analysis from Kansai Myeloma Forum. *Leukemia Res Rep*, 20 : 100395, 2023. (IF= 0.7)
- 3 Katsuragawa-Taminishi Y, Mizutani S, Kawaji-Kanayama Y, Onishi A, Okamoto H, Isa R, Mizuhara K, Muramatsu A, Fujino T, Tsukamoto T, Shimura Y, Taniwaki M, Miyagawa-Hayashino A, Konishi E, Kuroda J. Triple targeting of RSK, AKT, and S6K as pivotal downstream effectors of PDPK1 by TAS0612 in B-cell lymphomas. *Cancer Sci*, 114 : 4691-4705, 2023. (IF= 4.5)
- 4 Shimura Y, Shibayama H, Nakaya A, Yamamura R, Imada K, Kaneko H, Hanamoto H, Fuchida SI, Tanaka H, Kosugi S, Kiyota M, Matsui T,

- Kanda J, Iida M, Matsuda M, Uoshima N, Shibano M, Karasuno T, Hamada T, Ohta K, Ito T, Yagi H, Yoshihara S, Shimazaki C, Nomura S, Hino M, Takaori-Kondo A, Matsumura I, Kanakura Y, Kuroda J. Real-world data on induction therapy in patients with transplant-ineligible newly diagnosed multiple myeloma: retrospective analysis of 598 cases from Kansai Myeloma Forum. *Int J Hematol* 118 : 609–617, 2023. (IF= 1.8)
- 5 Inoue Y, Okamoto H, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida S, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J, and KOTOSG investigators. Clinical impacts of severe thrombocytopenia in the first cycle of azacitidine monotherapy and cytogenetics in patients with myelodysplastic syndrome: the Kyoto Conditional Survival Scoring System. *Oncol Lett* 27 : 62, 2023. (IF= 2.5)
 - 6 Onishi A, Muramatsu A, Shimura Y, Murao T, Fujino T, Mizutani S, Tsukamoto T, Shishido-Hara Y, Kuroda J. Progressive Multifocal Leukoencephalopathy Initially Suspected As Brain Relapse From Classical Hodgkin' s Lymphoma. *Cureus* 15 : e44000, 2023. (IF= 1.2)
 - 7 Mizuhara K, Shimura Y, Tsukamoto T, Kanai A, Kuwahara-Ota S, Yamaguchi J, Muramatsu A, Okamoto H, Taminishi-Katsuragawa Y, Kawaji-Kanayama Y, Isa R, Mizutani S, Inaba T, Kuroda J. Tumor-derived exosomes promote the induction of monocytic myeloid-derived suppressor cells from peripheral blood mononuclear cells by delivering miR-106a-5p and miR-146a-5p in multiple myeloma. *Br J Haematol* 203 : 426–438, 2023. (IF= 5.1)
 - 8 Okamoto H, Inoue Y, Miyashita A, Kawaji-Kanayama Y, Chinen S, Fujino T, Tsukamoto T, Shimura Y, Mizutani S, Kaneko H, Kuwahara-Ota S, Fuchida S, Nishiyama D, Hirakawa K, Uchiyama H, Uoshima N, Kawata E, Kuroda J, and KOTOSG investigators. Real-World Practice-Based Prognostic Model for Higher-Risk Myelodysplastic Syndromes Treated with Azacitidine Monotherapy: the Kyoto Prognostic Scoring System. *Int J Hematol* 118 : 323–332, 2023. (IF= 1.8)
 - 9 Inoue Y, Fujino T, Chinen S, Niiyama-Uchibori Y, Ide D, Kawata M, Hashimoto K, Takimoto-Shimomura T, Nakayama A, Tsukamoto T,

- Mizutani S, Shimura Y, Hirano S, Kuroda J. Cervical Local Cytokine Release Syndrome Following Chimeric Antigen Receptor T-cell Therapy in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma. *Cureus* 15 : e38905, 2023. (IF= 1.2)
- 10 Uno S, Midorikawa S, Inoue K, Ichikawa D, Ito T, Kuroda J, Suzuki K. Survival outcomes among patients with multiple myeloma in the era of novel agents: exploratory assessment using an electronic medical record database in Japan. *PLoS One* 18 : e0295947, 2023. (IF= 2.9)
 - 11 Shimazu Y, Kosugi S, Ito T, Kaneko H, Imada K, Shimura Y, Fuchida S, Fukushima K, Tanaka H, Yoshihara S, Ohta K, Uoshima N, Yagi H, Shibayama H, Yamamura R, Tanaka Y, Uchiyama H, Onda Y, Adachi Y, Hanamoto H, Takahashi R, Matsuda M, Miyoshi T, Takakuwa T, Hino M, Hosen N, Nomura S, Shimazaki C, Matsumura I, Takaori-Kondo A, Kuroda J. Efficacy of elotuzumab for multiple myeloma in reference to lymphocyte counts and kappa/lambda ratio or $\beta 2$ microglobulin. *Sci Rep* 13 : 5159, 2023. (IF= 3.8)
 - 12 Tsukamoto T, Kinoshita M, Yamada K, Ito H, Yamaguchi T, Chinen Y, Mizutani S, Fujino T, Kobayashi T, Shimura Y, Inazawa J, Kuroda J. Imaging flow cytometry-based multiplex FISH for three IGH translocations in multiple myeloma. *J Hum Genet* 114 : 2098–2108, 2023. (IF= 2.6)
 - 13 Hosono N, Chi S, Yamauchi T, Fukushima K, Shibayama H, Katagiri S, Gotoh A, Eguchi M, Morishita T, Ogasawara R, Kondo T, Yanada M, Yamamoto K, Kobayashi T, Kuroda J, Usuki K, Utsu Y, Yoshimitsu M, Ishitsuka K, Ono T, Takahashi N, Iyama S, Kojima K, Nakamura Y, Fukuhara S, Izutsu K, Abutani H, Yamauchi N, Yuda J, Minami Y. Clinical utility of genomic profiling of AML using paraffin-embedded bone marrow clots: HM-SCREEN-Japan 01. *Cancer Sci* 114 : 2098–2108, 2023. (IF= 4.5)
 - 14 Onishi A, Matsumura-Kimoto Y, Mizutani S, Tsukamoto T, Fujino T, Miyashita A, Nishiyama D, Shimura K, Kaneko H, Kawata E, Takahashi R, Kobayashi T, Uchiyama H, Uoshima N, Nukui Y, Shimura Y, Inaba T, Kuroda J. Impact of treatment with anti-CD20 monoclonal antibody on the production of neutralizing antibody against anti-SARS-CoV-2 vaccination in mature B-cell neoplasms. *Infect Drug Resist* 16 :

- 509–519, 2023. (IF= 2.9)
- 15 Wakita S, Marumo A, Morita K, Kako S, Toya T, Najima Y, Doki N, Kanda J, Kuroda J, Mori S, Satake A, Usuki K, Ueki T, Uoshima N, Kobayashi Y, Kawata E, Nakayama K, Nagao Y, Shono K, Shibusawa M, Tadokoro J, Hagihara M, Uchiyama H, Uchida N, Kubota Y, Kimura S, Nagoshi H, Ichinohe T, Kurosawa S, Motomura S, Hashimoto A, Muto H, Sato E, Ogata M, Mitsuhashi K, Ando J, Tashiro H, Sakaguchi M, Yui S, Arai K, Kitano T, Miyata M, Arai H, Kanda M, Itabashi K, Fukuda T, Kanda Y, Yamaguchi H. Mutational analysis of DNMT3A improves the prognostic stratification of patients with acute myeloid leukemia. *Cancer Sci* 114 : 1297–1308, 2023. (IF= 4.5)
 - 16 Onishi A, Shimura Y, Nakamura T, Souri M, Osaki T, Mizutani S, Tsukamoto T, Kobayashi T, Ichinose A, Kuroda J. Management of acquired factor X deficiency caused by in vitro non-neutralizing anti-factor X autoantibodies with pre-emptive corticosteroid therapy. *Intern Med* 62 : 2401–3406, 2023. (IF= 1.0)
 - 17 Inoue Y, Hirakawa K, Hayata H, Nishiyama D, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Kuroda J. Neurolymphomatosis of cranial nerves as the responsible lesions for the vocal cord paralysis and facial nerve palsy in a patient with diffuse large B-cell lymphoma. *Ann Hematol* 102 : 481–482, 2023 (IF= 3.0)
 - 18 Rai S, Kim WS, Ando K, Choi I, Izutsu K, Tsukamoto N, Yokoyama M, Tsukasaki K, Kuroda J, Ando J, Hidaka M, Koh Y, Shibayama H, Uchida T, Yang DH, Ishitsuka K, Ishizawa K, Kim JS, Lee HG, Minami H, Eom HS, Kurosawa M, Lee JH, Lee JS, Lee WS, Nagai N, Shindo T, Yoon DH, Yoshida S, Gillings M, Onogi H, Tobinai K. Oral HDAC inhibitor tucidinostat in patients with relapsed or refractory peripheral T-cell lymphoma: phase IIb results. *Haematologica* 108 : 811–821, 2023 (IF= 8.2)
 - 19 Fukuhara N, Maruyama D, Hatake K, Nagai H, Makita S, Kamezaki K, Uchida T, Kusumoto S, Kuroda J, Iriyama C, Yanada M, Tsukamoto N, Suehiro Y, Minami H, Garcia-Vargas J, Childs BH, Yasuda M, Masuda S, Tsujino T, Terao Y, Tobinai K. The safety and antitumor activity of copanlisib in Japanese patients with relapsed/refractory indolent non-Hodgkin lymphoma: a phase Ib/II study. *Int J Hematol* 117 : 100–109, 2023. (IF= 1.8)

- 20 Arai K, Sakaguchi M, Yui S, Kitano T, Miyata M, Yogosawa M, Nakayama K, Tajika K, Usuki K, Kuroda J, Uoshima N, Kobayashi Y, Uchiyama H, Kubota Y, Kimura S, Mori S, Hirai M, Wakita S, Yamaguchi H. Simultaneous detection of JAK2, CALR, and MPL mutations and quantitation of JAK2 V617F allele burden in myeloproliferative neoplasms using the quenching probe-Tm method in i-densy IS-5320. *Int J Lab Hematol* 44 : 1102-1110, 2023. (IF= 2.2)
- 21 Mizuhara K, Kobayashi T, Nakao M, Takahashi R, Kaneko H, Shimura K, Hirakawa K, Uoshima N, Wada K, Kawata E, Isa R, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Yoneda A, Watanabe A, Sotozono C, Kuroda J. Watchful waiting is an acceptable treatment option for asymptomatic primary ocular adnexal mucosa-associated lymphoid tissue lymphoma: a retrospective study. *Cancer Med* 12 : 3134-3144, 2023. (IF= 2.9)
- 22 Jo T, Yoshihara S, Okuyama Y, Fujii K, Henzan T, Kahata K, Yamazaki R, Takeda W, Umezawa Y, Fukushima K, Ashida T, Yamada-Fujiwara M, Hanajiri R, Yonetani N, Tada Y, Shimura Y, Nishikii H, Shiba N, Mimura N, Ando J, Sato T, Nakashima Y, Ikemoto J, Iwaki K, Fujiwara SI, Ri M, Nagamura-Inoue T, Tanosaki R, Arai Y. Risk factors for CAR-T cell manufacturing failure among DLBCL patients: A nationwide survey in Japan. *Br J Haematol* 202 : 256-266, 2023 (IF 5.1)
- 23 Souri M, Osaki T, Shimura Y, Ichikawa S, Mori M, Ogawa Y, Ichinose A. Identification of non-neutralizing anti-factor X autoantibodies in three Japanese cases of autoimmune acquired factor X deficiency. *Haemophilia* 29 : 555-563, 2023 (IF 3.0)
- 24 Takimoto-Ito R, Kambe N, Kogame T, Nomura T, Izawa K, Jo T, Kazuma Y, Yoshifuji H, Tabuchi Y, Abe H, Yamamoto M, Nakajima K, Tomita O, Yagi Y, Katagiri K, Matsuzaka Y, Takeuchi Y, Hatanaka M, Kanekura T, Takeuchi S, Kadono T, Fujita Y, Migita K, Fujino T, Akagi T, Mukai T, Nagano T, Kawano M, Kimura H, Okubo Y, Morita A, Hide M, Satoh T, Asahina A, Kanazawa N, Kabashima K. Summary of the current status of clinically diagnosed cases of Schnitzler syndrome in Japan. *Allergol Int.* 2023 Apr;72(2):297-305. (IF 6.2)
- 25 Potts MA, Mizutani S, Garnham AL, Li Wai Suen CSN, Kueh AJ, Tai L, Pal M, Strasser A, Herold MJ; Deletion of the transcriptional

regulator TFAP4 accelerates c-MYC-driven lymphomagenesis. Cell Death Differ. 2023 30:1447-1456. (IF=12.4)

(C-b) 和文原著
なし

(D) 学会発表等

I) 招待講演、特別講演、教育講演等

- 1 志村勇司. 第 85 回日本血液学会学術集会 教育講演 EL3-4-5
「骨髄腫の骨髄微小環境における免疫抑制系細胞の役割」

II) シンポジウム、ワークショップ、パネルディスカッション等

- 1 Kuroda J. Current status and challenges with clinical practice for multiple myeloma in Japan. Asian Joint Panel Discussion. 第 85 回日本血液学会学術総会, 2023, 東京.
- 2 Kuroda J. Emerging Clinical and Research Issues in the era of CAR-T Cell Therapy for Multiple Myeloma. JSHCT-KSBMT Joint Symposium. 第 45 回日本造血・免疫細胞療法学会総会, 2023, 名古屋.

III) 国際学会における一般発表

- 1 Idai T. Comparing radon daughter dosimetric and risk models. Seventh Life Science Symposium. 2023 Oct 29-31; ○○○○○, USA
(注 会議の開催都市名、国名、ただし国内の場合国名は省略) .
- 2 Ohmachi K, Kinoshita T, Maruyama D, Ogawa G, Sano Y, Yamauchi N, Fukuhara N, Uchida T, Yamamoto K, Miyazaki K, Tsukamoto N, Iida S, Yoshida I, Suzuki Y, Masaki Y, Murayama T, Yakushijin Y, Suehiro Y, Nosaka K, Dobashi N, Kuroda J, Munakata W. Ando K, Ishizawa K, Ogura M, Yoshino T, Hotta T, Tsukasaki K, Tobinai K, Nagai H. ° Final Analysis of the Randomized Phase II/III Study of Standard R-CHOP Versus CHOP Combined with Dose-Dense Weekly Rituximab for DLBCL: JCOG0601. The American Society of Hematology 65th Annual Meeting and Exposition. 2023 Dec 9-12 ; San Diego, USA.
- 3 Toubai T, Kuroda J, Suehiro Y, Mishima Y, Sunami K, Kato K, Uoshima N, Kumode T, Ota A, Mitsuki K, Yokota D, Sano Y, Terui Y. A Phase 1 Trial of OPB-111077 in Combination with Bendamustine (B) and Rituximab (R) in Patients with Relapsed or Refractory (R/R) Diffuse

- Large B-Cell Lymphoma (DLBCL): Preliminary Results of Dose-Escalation Stage The American Society of Hematology 65th Annual Meeting and Exposition. 2023 Dec 9-12 ; San Diego, USA.
- Okamoto H, Mizutani S, Tsukamoto T, Katsuragawa-Taminishi Y, Isa R, Mizuhara K, Muramatsu A, Kawaji-Kanayama Y, Fujino T, Shimura Y, Kuroda J. TAS0612, a Triple Inhibitor for RSK, AKT, and S6K, Is a Promising Anti-Myeloma Agent Regardless of Types of Cytogenetic/Genetic Abnormality The American Society of Hematology 65th Annual Meeting and Exposition. 2023 Dec 9-12 ; San Diego, USA.
- 4 Onishi A, Miyagawa-Hayashino A, Mizuhara K, Muramatsu A, Okamoto H, Kawaji-Kanayama Y, Katsuragawa-Taminishi Y, Fujino T, Tsukamoto T, Mizutani S, Shimura Y, Konishi E, Kuroda J. The Activation Status of RSK2, but Not PDPK1 and AKT, Associates with the Prognosis of Diffuse Large B Cell Lymphoma. The American Society of Hematology 65th Annual Meeting and Exposition. 2023 Dec 9-12 ; San Diego, USA.
 - 5 Kogure Y, Handa H, Ito Y, Ri M, Horigome Y, Iino M, Harazaki Y, Kobayashi T, Abe M, Ishida T, Ito S, Iwasaki H, Kuroda J, Shibayama H, Sunami K, Takamatsu H, Tamura H, Hayashi T, Akagi K, Shinozaki T, Yoshida T, Mori I, Iida S, Maeda T, Kataoka K. CIRCULATING TUMOR DNA ASSESSMENT IMPROVES PROGNOSTIC PREDICTION IN RELAPSED/REFRACTORY MULTIPLE MYELOMA RECEIVING IXAZOMIB, LENALIDOMIDE, AND DEXAMETHASONE. European Hematology Association. 2023 June 8-11 ; Frankfurt, Germany.
 - 6 Richardson PG, Amatangelo M, Berenson JR, Cerchione C, Dimopoulos MA, Hansen CT, Hwang SJ, Koo P, Kuroda J, Oriol A, Orlowski RZ, Quach H, Raab MS, Rocci A, Wang Y, White D, Yu B, Zhou Z, Katz J. A phase 3, two-stage, randomized study of mezigdomide, carfilzomib, and dexamethasone (MeziKd) versus carfilzomib and dexamethasone (Kd) in relapsed/refractory multiple myeloma (RRMM): SUCCESSOR-2. The American Society of Clinical Oncology 2023 Annual Meeting. 2023 June 2-6 ; Chicago, USA.
 - 7 Kawaji-Kanayama Y, Tsukamoto T, Nakano M, Tokuda Y, Nagata H, Mizuhara K, Katsuragawa-Taminishi Y, Isa R, Fujino T, Matsumura-Kimoto Y, Mizutani S, Shimura Y, Taniwaki M, Tashiro K,

Kuroda J. BTG2, A NOVEL TARGET OF MIR-17-92, REGULATES B CELL RECEPTOR SIGNALING IN MANTLE CELL LYMPHOMA. European Hematology Association. 2023 June 8-11 ; Frankfurt, Germany.

- 8 Fujimoto A, Miyazaki K, Taguchi S, Asano N, Yakushijin K, Fujino T, Munakata W, Ejima Y, Hirano M, Kubota N, Takizawa J, Hiramoto N, Takeuchi M, Sakai R, Fukuhara N, Yamaguchi M, Suzuki R. (2023), Improved prognosis of advanced-stage extranodal NK/T-cell lymphoma: results of the NKEA-Next study. The 17th International Conference on Malignant Lymphoma. 2023 June 13-17; Lugano, Switzerland.

E 研究助成（競争的研究助成金）

総額 574 万円

公的助成

代表（総額）・小計 370 万円

1. 黒田純也 文部科学省科学研究費補助金基盤研究（C） 令和 4～6 年度
全ての成熟リンパ系腫瘍の制御に向けた RSK2/AKT/S6K 同時標的治療薬の開発 助成金額 90 万円
2. 塚本拓 文部科学省科学研究費補助金若手研究 令和 3～5 年度
Galectin-9 を介したマンツル細胞リンパ腫の BCR シグナル活性化機序の解明 助成金額 80 万円
3. 志村勇司 文部科学省科学研究費補助金基盤研究（C） 令和 4～6 年度
造血器腫瘍における MDSC を標的とした miRNA インヒビターカクテル療法の開発 助成金額 90 万円
4. 水谷信介 文部科学省科学研究費補助金若手研究 令和 5～7 年度
成熟 B 細胞性腫瘍における病態促進性インターフェロン刺激遺伝子の同定と制御戦略開発 助成金額 110 万円

分担・小計 104 万円

1. 黒田純也 AMED 革新的がん医療実用化研究事業 令和 3～6 年度
高齢者多発性骨髄腫に対する標準治療の確立と治療効果・耐性獲得に関わる分子基盤の探索 助成金額 20 万円
2. 黒田純也 AMED 臨床研究・治験推進研究事業 令和 2～5 年度

急性骨髄性白血病に対する治療用がんペプチドワクチン「DSP-7888」の
Phase2 医師主導治験 助成金額 840,833 円

財団等からの助成

代表（総額）・小計 100 万円

- 1 黒田純也. 令和 5 年度京都健康管理研究会研究助成. 令和 5 年度
難治造血器悪性腫瘍に対する細胞免疫療法の効果減弱・抵抗性獲得を克服
するための普遍的抗腫瘍免疫再教育戦略の開発. 助成金額 100 万円.